Enhanced Alpha-Emitter Radiation Therapy with Advanced Beta Treatment
Legal Citation
Summary of the Inventive Concept
This inventive concept presents a novel approach to alpha-emitter radiation therapy by introducing advanced beta treatment enhancements, resulting in improved safety, efficiency, and treatment outcomes.
Background and Problem Solved
The original patent, 'Diffusing alpha-emitter radiation therapy with enhanced beta treatment', provided a foundation for implantable radiation sources with combined alpha and non-alpha radiation. However, the original design had limitations in controlling radionuclide desorption and optimizing beta radiation intensity. This new inventive concept addresses these limitations by introducing novel nano-porous coatings, localized electric fields, and tunable composite materials to enhance beta treatment and improve overall therapy efficiency.
Detailed Description of the Inventive Concept
The enhanced alpha-emitter radiation therapy system comprises a radiation source with a novel nano-porous coating for controlled release of radionuclide atoms and daughter radionuclides. A sensor monitors the desorption probability of radon release, enabling real-time adjustments. Additionally, a localized electric field can be applied to stimulate the desorption of daughter radionuclides, increasing the beta radiation intensity. The system can also utilize a novel composite material with a tunable desorption probability, allowing for real-time adjustments. A computer algorithm predicts the desorption probability based on material properties and environmental conditions, optimizing the therapy. Furthermore, a novel radiation-absorbing material reduces systemic alpha radiation, ensuring improved safety.
Novelty and Inventive Step
The new claims introduce novel components and methods that significantly improve the original patent's design. The use of nano-porous coatings, localized electric fields, and tunable composite materials provides a non-obvious solution to the limitations of the original patent, offering enhanced beta treatment and improved therapy efficiency.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include varying the nano-porous coating's structure, using different types of localized electric fields, or incorporating additional sensors to monitor the radiation source's performance. These variations would ensure broad conceptual coverage and adaptability to different treatment scenarios.
Potential Commercial Applications and Market
This inventive concept has significant commercial potential in the radiotherapy market, particularly in the treatment of malignant cancerous tumors. The enhanced alpha-emitter radiation therapy system could be marketed as a premium product, offering improved safety, efficiency, and treatment outcomes. Target industries include hospitals, cancer research centers, and medical device manufacturers.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Radiation therapy and medical device design, specifically interstitial radiation sources with radionuclide delivery systems, requiring expertise in nuclear medicine, materials science, and radiation physics
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or medical physicist with advanced degrees, experience in radiation therapy device design, understanding of radionuclide decay processes, and knowledge of materials engineering for controlled radiation delivery
Obviousness Rationale
A PHOSITA would recognize the PTD's variations as straightforward extensions of the source patent's core radiation therapy technology. The proposed nano-porous coatings, electric field stimulation, and desorption monitoring represent predictable engineering improvements to the existing alpha-emitter radiation source design. These modifications address known limitations in radiation therapy by providing more precise control over radionuclide release and radiation intensity.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,803 |
|---|---|
| Title | Diffusing alpha-emitter radiation therapy with enhanced beta treatment |
| Assignee(s) | Alpha Tau Medical Ltd |